News23 March 2026

Roquefort Therapeutics targets cancel treatment with £32m deal

By Embue UK Editor2 min read

LONDON: Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for...

Subscriber story

Subscribe to read the full report

Continuous, comprehensive intelligence on UK care & health — the sector in full. · around 28 stories a week

Independent reporting for the UK care & health sector. Subscribe for unlimited access to news, analysis, legal and HR.